Accolade, Inc. (NASDAQ:ACCD) EVP Sells $21,375.98 in Stock

Accolade, Inc. (NASDAQ:ACCD) EVP Richard Eskew sold 3,229 shares of the firm’s stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $6.62, for a total transaction of $21,375.98. Following the sale, the executive vice president now owns 48,478 shares in the company, valued at $320,924.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Richard Eskew also recently made the following trade(s):

• On Thursday, May 2nd, Richard Eskew sold 462 shares of Accolade stock. The stock was sold at an average price of $7.28, for a total value of $3,363.36.

Accolade Trading Down 4.2 %

Shares of ACCD stock opened at $6.18 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.64 and a current ratio of 2.64. Accolade, Inc. has a fifty-two week low of $6.18 and a fifty-two week high of $15.36. The company has a market cap of $484.26 million, a PE ratio of -4.65 and a beta of 2.10. The stock’s fifty day moving average price is $7.69 and its two-hundred day moving average price is $9.89.

Accolade (NASDAQ:ACCD) last released its quarterly earnings data on Thursday, April 25th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.01. The business had revenue of $124.80 million for the quarter, compared to analyst estimates of $123.91 million. Accolade had a negative return on equity of 22.53% and a negative net margin of 24.09%. Accolade’s revenue was up 26.1% compared to the same quarter last year. During the same period last year, the firm posted ($0.42) earnings per share. Equities analysts predict that Accolade, Inc. will post -1.23 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on ACCD. Leerink Partnrs reaffirmed an “outperform” rating on shares of Accolade in a research report on Monday, February 26th. Guggenheim decreased their price target on shares of Accolade from $17.00 to $13.00 and set a “buy” rating for the company in a research note on Wednesday, May 8th. SVB Leerink began coverage on shares of Accolade in a report on Monday, February 26th. They issued an “outperform” rating and a $16.00 price objective on the stock. Barclays reduced their target price on shares of Accolade from $13.00 to $11.00 and set an “equal weight” rating for the company in a report on Friday, April 26th. Finally, Truist Financial lowered their price target on shares of Accolade from $16.00 to $14.00 and set a “buy” rating on the stock in a research note on Friday, April 26th. Four analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat, Accolade has an average rating of “Moderate Buy” and an average price target of $14.14.

Institutional Trading of Accolade

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. DekaBank Deutsche Girozentrale acquired a new stake in shares of Accolade during the 3rd quarter valued at $28,000. AJOVista LLC bought a new position in Accolade in the fourth quarter valued at about $68,000. Allspring Global Investments Holdings LLC acquired a new stake in shares of Accolade during the first quarter valued at about $87,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Accolade by 39.0% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,584 shares of the company’s stock worth $199,000 after purchasing an additional 4,656 shares during the last quarter. Finally, GGV Capital LLC increased its stake in shares of Accolade by 242.9% in the first quarter. GGV Capital LLC now owns 18,063 shares of the company’s stock valued at $189,000 after buying an additional 12,795 shares during the period. Institutional investors own 84.99% of the company’s stock.

About Accolade

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians.